Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sensorion has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are handled by 2 distinct examiners, ensuring that each matter receives individual attention from different personnel. Both actions are situated within 1 distinct art unit, which may lead to consistent legal interpretations across the portfolio. SHTERENGARTS, SAMANTHA L is identified as the busiest examiner, managing 1 pending office action for the company. This distribution balances the workload across the available examiners.
The concentration of 2 pending office actions in 1 distinct art unit suggests a specialized focus within Biotechnology & Pharmaceuticals. While 2 distinct examiners are involved, the shared art unit environment may result in similar prosecution hurdles. SHTERENGARTS, SAMANTHA L handles 1 pending office action, representing half of the current docket. Practitioners should coordinate responses to maintain a unified strategy within the single art unit. This approach helps ensure that the company's technical arguments remain consistent across both pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
| DRAPER, LESLIE A ROYDS | 1 | 27.3% | +43.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18182511 | METHOD OF PREVENTING COCHLEAR DISEASE, DISORDER OR CONDITION USING (+)-AZASETRON | DRAPER, LESLIE A ROYDS | 131d overdue |
| 18840560 | AZASETRON FOR THE TREATMENT OF SUDDEN SENSORINEURAL HEARING LOSS | SHTERENGARTS, SAMANTHA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18182511 | METHOD OF PREVENTING COCHLEAR DISEASE, DISORDER OR CONDITION USING (+)-AZASETRON | DRAPER, LESLIE A ROYDS | 131d overdue |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18840560 | AZASETRON FOR THE TREATMENT OF SUDDEN SENSORINEURAL HEARING LOSS | SHTERENGARTS, SAMANTHA L | — | §102§103§112 | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18182511 | METHOD OF PREVENTING COCHLEAR DISEASE, DISORDER OR CONDITION USING (+)-AZASETRON | DRAPER, LESLIE A ROYDS | 1629 | §102§103 | Final Rejection | 131d overdue | Pending | Mar 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial